ProCE Banner Activity

NAPOLI 3: Phase III Trial of First-line NALIRIFOX vs Nab-Paclitaxel + Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Conference Coverage
Slideset

Released: January 30, 2023

Expiration: January 29, 2024

No longer available for credit.
Begin Activity

Share

Provided by

ProCE Banner

Supporters

This activity is supported by educational grants from

Bristol Myers Squibb

Incyte Corporation

Seagen Inc.